You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 353 Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
353 Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020254030
Dec 20205908
Jan 20214809
Feb 202152011
Mar 202174014
Apr 202180022
May 202121013
Jun 20210027
Jul 20210022
Aug 20210029
Sep 20210015
Oct 202194043
Nov 2021139032
Dec 202150010
Jan 202270026
Feb 202258020
Mar 202278014
Apr 2022104017
May 202270017
Jun 202252011
Jul 202264012
Aug 20226005
Sep 202246012
Oct 202254010
Nov 20222608
Dec 202244013
Jan 20234007
Feb 20237009
Mar 20234606
Apr 20231806
May 20234208
Jun 20232808
Jul 202344012
Aug 202356018
Sep 20233106
Oct 20235205
Nov 202376014
Dec 20238206
Jan 20242801
Feb 202496025
Mar 20245203
Apr 20249209
May 20247608
Jun 20247706
Jul 202484010
Aug 202468014
Sep 202448022
Oct 202452010
Nov 202491013
Dec 202483020
Jan 202596031
Feb 202522015
Mar 20250017
Apr 20250014
May 20251018
Jun 20250015
Total31480806